- Home
- INKT
as 07-26-2024 4:00pm EST
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 41.3M | IPO Year: | 2021 |
| Target Price: | $9.00 | AVG Volume (30 days): | 98.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $1.96 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MiNK Therapeutics Inc. News
INKT Breaking Stock News: Dive into INKT Ticker-Specific Updates for Smart Investing
Zacks
15 days ago
MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
GlobeNewswire
2 months ago
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
GlobeNewswire
2 months ago
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
GuruFocus.com
2 months ago
MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...
GlobeNewswire
2 months ago
MiNK Reports First Quarter 2024 Results
GlobeNewswire
2 months ago
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
GlobeNewswire
3 months ago
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
Simply Wall St.
3 months ago
This MiNK Therapeutics Insider Increased Their Holding In The Last Year
Compare INKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INKT MiNK Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.